Rudd Report Completes Research Report on AMDL
September 28 2006 - 2:00PM
PR Newswire (US)
TUSTIN, Calif., Sept. 28 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, announced today that The Rudd
Report, a division of Savannah Capital Management, has initiated
coverage on AMDL with a "buy" rating and a target price of at least
$5.40 for its post reverse common shares. Lauren Rudd, President of
Savannah Capital Management and publisher of The Rudd Report, has
more than three decades of experience in business and financial
research, investment analysis and professional writing. Savannah
Capital Management is a money management firm whose investment
returns have exceeded the performance of the S&P 500 Index
every year since the company's inception. Mr. Rudd's newspaper
columns about Wall Street are read by an estimated six million
readers daily. The Rudd Report is bullish about AMDL's future
partially because of the recent acquisition of Jade Pharmaceutical
Inc.'s two pharmaceutical companies headquartered in China. "Jade's
operations in China provide AMDL access to the fastest growing
pharmaceutical market in the world. Furthermore, this acquisition
places the company on the strongest financial footing we have seen
since its inception," Mr. Rudd concludes. The paid-for research
report will be updated on a quarterly basis and can be viewed at
http://www.ruddreport.com/amdl_main.htm . About AMDL AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, is a theranostics
company, involved in the detection and treatment of the same
disease, cancer. AMDL is the inventor, developer and worldwide
marketer through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 14 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdl.com/. Forward-Looking Statements This news release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024